H1N1 2009 Vaccine Manufacturing Process: Inactivated and Live-Attenuated

The 2009 H1N1 pandemic vaccines were produced via two platforms:

Inactivated (Split-Virion/Subunit) Vaccine

  1. Virus Collection: WHO-recommended seed strain from reference labs.
  2. Propagation: Growth in embryonated chicken eggs or mammalian cell culture.
  3. Harvest: Virus-containing allantoic fluid or cell supernatant collected.
  4. Inactivation: Formaldehyde or β-propiolactone destroys infectivity while preserving antigens.
  5. Purification: Centrifugation, filtration, chromatography remove host proteins, lipids, nucleic acids.
  6. Formulation: Antigen standardized; stabilizers, preservatives, and sometimes adjuvants (e.g., AS03, MF59) added.
  7. Quality Control: Sterility, potency (SRID), safety, endotoxin testing.
  8. Fill/Finish: Sterile vials/syringes; cold-chain distribution.

Live-Attenuated Influenza Vaccine (LAIV)

  1. Seed Virus: Same WHO strain.
  2. Attenuation: Cold-adapted, temperature-sensitive master donor virus (e.g., A/Ann Arbor/6/60) reassorted with H1N1 surface genes.
  3. Propagation: In embryonated eggs at 25–27°C.
  4. Harvest & Processing: Allantoic fluid pooled, clarified.
  5. Formulation: Stabilizers (sucrose, phosphate), preservatives; no adjuvant.
  6. Quality Control: Genetic stability, infectivity, temperature sensitivity, sterility.
  7. Distribution: Cold chain (2–8°C); intranasal sprayer device.

Both types underwent accelerated but rigorous clinical trials before emergency use authorization.

Viral Infections - Related Articles